Field MedicalIn the journal "Circulation》First announced its PFA ablation catheter ---FieldForceTreatmentClinical Data of Ventricular Tachycardia (VCAS). The research shows thatFieldForcePositive treatment outcomes.VCAS is a prospective, multi-center feasibility trial evaluating the safety and efficacy of FieldForce for patients with ventricular tachycardia. Unlike traditional techniques,FieldForceUtilizes a unique high-pressure short-pulse waveform capable of penetrating dense scar tissue while minimizing thermal damage.Specific Research Data (6 Months Post-Operative)- 82% of patients had no recurrence of ventricular tachycardia/ventricular fibrillation or received ICD treatment.
- Ventricular Tachycardia/Ventricular Fibrillation Episode Burden Reduced by 98%
- The incidence of major safety events was 11.5%, with no cases of treatment-related complications.
"Although still a preliminary feasibility study, the six-month results are encouraging. Achieving an 82% recurrence-free rate and a 98% reduction in arrhythmia burden through non-thermal, tissue-selective energy is significant for the treatment of ventricular tachycardia. More importantly, this is the first time that pulsed field ablation has been shown to penetrate deep into ventricular transmural scar tissue—a long-standing clinical challenge with current energy sources. These findings make me cautiously optimistic that, with continued optimization, this technology could become an important advancement in the treatment of scar-related ventricular tachycardia."---Vivey Reddy Mount Sinai
Executive Evaluation
"《Circulation》The journal rarely publishes early feasibility data, underscoring the rigor and significant value of this study. We remain committed to integrating scientific credibility with technological innovation. These findings mark an important milestone, and we will continue to evaluate the improvements in ventricular pulse field ablation technology.Potential of Prognosis in Patients with Atrial Arrhythmias."
---Steven Mickelsen Field MedicalFounder and Chief Technology Officer
Field MedicalIs currently one of the most sought-after PFA companies. Unlike many new forces in the PFA field, it does not focus on the most popular atrial fibrillation treatments but instead concentrates on the most challenging aspects of the electrophysiology field.Ventricular Tachycardia.Ventricular tachycardia and atrial fibrillation are two of the most common and serious types of arrhythmia diseases, but unlike atrial fibrillation,The current treatment options for ventricular tachycardia are very limited, and the existing treatment techniques often come with many complications, which are highly unsatisfactory.Field MedicalSeeing PFA in treatmentPotential for ventricular tachycardia, therefore proactive measures are being taken. Now we seeField MedicalPublication of the First Clinical Data Shows PFA TreatmentVentricular Tachycardia with Great Potential. PFA is not only highly effective but also extremely safe, which current treatment technologies cannot compare to.Visible PFA FatherSteven Mickelsen has a very unique understanding of PFA technology, currentlyField MedicalIn this field, facing Medtronic (Sphere-9), Boston Scientific (FaraFlex), Abbott (TactiFlex) and other competitors.But the capital market remains bullish.Field Medical, which has completed two rounds of financing this year alone, at $40 million and $35 million respectively. Both the clinical and capital sectors are highly anticipating.FieldForce，FieldForceReplicate the success of FARAPULSE (this product is alsoDeveloped by Steven Mickelsen）。FieldForceYesField MedicalThe core products, including catheters and energy generators.FieldForceYesThe world's first dedicated contact force focal PFA catheter,Can achieve instantaneous ablation operation (treatment time only takes milliseconds).Seconds). ItsOvercomeThe limitations of the first-generation PFA technology and the significant unmet need for treating any arrhythmia, not only capable of treating atrial fibrillation but also complex ventricular arrhythmias.To achieve one catheter for all treatmentsArrhythmia issues,Field MedicalDevelop a new technologyFieldBending, andFieldBendingTechnology forFieldForce。FieldBendingA technology that predictably concentrates energy around the catheter and reduces unwanted far-field effects, thereby improving efficacy and safety. Ultimately,FieldBendingThe ultra-targeted energy allows for more accurate and concentrated application of power to the target tissue, enabling deeper penetration of energy into the tissue and achieving a wider range of ablation.
Field MedicalIs an innovative company focused on the field of pulsed field catheter ablation. Founded by Dr. Steven Mickelsen in 2022, it is developing a patented technology called FieldBending, which aims to concentrate therapeutic effects and reduce the harmful far-field effects associated with first-generation PFA technology.Field MedicalAiming to expand the indications of pulsed field ablation (PFA) beyond atrial fibrillation treatment by addressing more challenging ventricular arrhythmias and common procedures such as supraventricular tachycardia (SVT) that require minimal sedation.
